^
Association details:
| Biomarker: | SF3B1 K666N |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Xpovio (selinexor) (XPO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1341 - Inhibiting the nuclear exporter XPO1 and the antiapoptotic factor BCL2 is synergistic in XPO1 and SF3B1 mutant hematologic malignancies
Published date:
03/10/2021
Excerpt:
Five lymphoma cell lines; 3 diffuse large B-cell lymphoma (SU-DHL-6, SU-DHL-16, FARAGE) and 2 classical Hodgkin lymphoma (L428 and SUP-HD1), were used based on the presence or absence of XPO1 mutations. SUDHL-16 and SUP-HD1 are heterozygous for the XPO1 E571K hotspot mutation while SUDHL-6, FARAGE and SUP-HD1 are wildtype. These cell lines were used to assess sensitivity to Selinexor or Venetoclax using the CellTiter Glo assay. Next, we tested the synergy of the combination of these drugs in the XPO1 and SF3B1 mutant cell lines….SF3B1 K666N mutant K562 and Nalm-6 cells also showed increased sensitivity to selinexor compared to wildtype cells...the combination of Selinexor and venetoclax showed synergy in both the XPO1 and SF3B1 mutant cell lines…
